A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for

Status Recruiting

Clinical Trial Summary

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis

Clinical Trial Description

Immune nephritis is a chronic glomerular disease originating in the kidney caused by various etiologies.Clinically, secondary chronic kidney damage caused by systemic diseases such as diabetes, systemic lupus erythematosus and gout is named after its primary disease, such as diabetic nephropathy and lupus nephritis. Autoimmune diseases only show local pathological damage, but more often systemic lesions. If not diagnosed and treated in time or poorly controlled, a risk of disability or even death as the course of the disease progresses. Studies have shown that B cells can present their own antigens to autoimmune T cells to promote the release of inflammatory factors, or they can differentiate into plasma cells to release autoantibodies, and play an important role in the occurrence and progression of autoimmune diseases. In recent years, it has become a major research focus to deplete B cells in patients or inhibit B cell function. This research focuses on CAR-T cells killing B cells. Based on the current research progress, our center intends to conduct research on the safety and effectiveness of CD19/BCMA CAR-T cells in the treatment of refractory systemic lupus erythematosus. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05085418
Study type	Interventional
Source	Zhejiang University
Contact	He Huang, PhD
Phone	86-13605714822
Email	hehuangyu@126.com
Status	Recruiting
Phase	Early Phase 1
Start date	November 5, 2021
Completion date	November 5, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04078698` - Documentation of the Safety and Effectiveness Profile of the IgG Immunoadsorber GLOBAFFIN® in Clinical Routine	N/A
Recruiting	`NCT04039763` - RT-CGM in Young Adults at Risk of DKA	N/A
Recruiting	`NCT05670301` - Flemish Joint Effort for Biomarker pRofiling in Inflammatory Systemic Diseases	N/A
Completed	`NCT03266172` - A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses	Phase 1
Completed	`NCT03649412` - A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772	Phase 1
Recruiting	`NCT04561557` - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System	Early Phase 1
Completed	`NCT03173144` - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Completed	`NCT00975936` - Phase 0 Microdose Study	Phase 1
Not yet recruiting	`NCT05969821` - Clonal Hematopoiesis of Immunological Significance
Completed	`NCT01210716` - Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device	Phase 3
Completed	`NCT00820469` - Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab	Phase 4
Completed	`NCT01953523` - Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions	N/A
Withdrawn	`NCT03239600` - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS)	Phase 2
Completed	`NCT04872257` - Oral Vitamin D Supplementation Combined With Phototherapy as a Treatment for Vitiligo	N/A
Recruiting	`NCT06019611` - Epidural Stimulation in Multiple Sclerosis	N/A
Recruiting	`NCT05030779` - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus	Early Phase 1
Not yet recruiting	`NCT03899298` - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions	Phase 1
Completed	`NCT04005456` - Personalized Lifestyle Intervention for Improving Functional Health Outcomes Using N-of-1 Tent-Umbrella-Bucket Design	N/A
Recruiting	`NCT05085444` - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma	Early Phase 1
Recruiting	`NCT05853835` - First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641	Phase 1